Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725531 | 0.88 | ALDH1A1 (0.33) | ALDH1A1CYP1A2CYP3A4CYP2C19MCHR1 | |
| SCHEMBL21725529 | 0.81 | NCF1 (0.36) | ALDH1A1CYP1A2CYP3A4CYP2C19MCHR1 | |
| SCHEMBL23717592 | 0.79 | MCHR1 (0.37) | MCHR1 | |
| SCHEMBL21725548 | 0.78 | PDE10A (0.40) | — | |
| SCHEMBL23251413 | 0.78 | HPGD (0.35) | — | |
| SCHEMBL22193256 | 0.77 | AR (0.38) | CYP1A2CYP3A4MCHR1NCF1 | |
| SCHEMBL22193274 | 0.75 | CACNA1C (0.39) | — | |
| SCHEMBL21725463 | 0.73 | IDH1 (0.36) | — | |
| SCHEMBL22871165 | 0.72 | NCF1 (0.39) | ALDH1A1CYP1A2CYP3A4CYP2C19MCHR1 | |
| SCHEMBL23717826 | 0.71 | SCN5A (0.44) | ALDH1A1CYP1A2CYP3A4CYP2C19MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | ALDH1A1 2977/4885CYP1A2 1383/4885CYP3A4 2798/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | ALDH1A1 2977/4885CYP1A2 1383/4885CYP3A4 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.